海南双成药业股份有限公司 董事、高级管理人员薪酬管理制度 海南双成药业股份有限公司 董事、高级管理人员薪酬管理制度 （2025 年 4 月修订） 第一章 总则 第一条 为进一步完善海南双成药业股份有限公司（以下简称"公 司"）董事、高级管理人员的薪酬管理，建立有效的激励与约束机制， 有效地调动公司董事、高级管理人员工作积极性，提高企业经营管理 水平，促进企业效益的增长，根据《中华人民共和国公司法》、《上市 公司治理准则》等有关法律、法规、规范性文件及《公司章程》的规 定，结合本公司的实际情况，制定本制度。 第二条 本制度适用于《公司章程》规定的董事、高级管理人员。 第三条 公司董事、高级管理人员薪酬管理遵循以下原则： （一）公平原则：体现收入水平符合公司规模与业绩的原则，同 时兼顾市场薪酬水平； （二）责、权、利统一原则：体现薪酬与岗位价值高低、履行责 任义务大小相符； （三）长远发展原则：体现薪酬与公司持续健康发展的目标相符； （四）激励约束并重原则：体现薪酬发放与考核、奖惩挂钩，与 公司激励机制挂钩。 第二章 薪酬管理机构 第四条 公司董事会薪酬与考核委员会负责制定公司董事、高级 海南双成药业股份有限公司 ...

海南双成药业股份有限公司 海南双成药业股份有限公司 董事会议事规则 董事会议事规则 （2025 年 4 月修订） 第一章 总则 第一条 为明确海南双成药业股份有限公司（以下简称"公司"）董事会的 职责权限，规范董事会的组织和行为，确保董事会的工作效率和科学决策，根据 《中华人民共和国公司法》（以下简称"公司法"）和《海南双成药业股份有限 公司章程》（以下简称"公司章程"）的规定，制定本规则。 第二条 董事会是公司的常设机构，对股东会负责，执行股东会决议，维护 公司和全体股东的利益，负责公司发展目标和重大经营活动的决策。 第二章 董事 第三条 董事为自然人。有下列情形之一的，不能担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓刑的， 自缓刑考验期满之日起未逾二年； （三）担任破产清算的公司、企业的董事或者厂长、总经理，对该公司、企 业的破产负有个人责任的，自该公司、企业破产清算完结之日起未逾 3 年； （四）担任因违法被吊销营业执照、责令关闭的公司、企业的法定代 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥36,675,823.05, a decrease of 14.23% compared to ¥42,761,740.63 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥10,040,496.02, representing a decline of 14.84% from a loss of ¥8,742,676.77 in the previous year[4] - The company's basic and diluted earnings per share were both -¥0.0242, a decrease of 14.69% from -¥0.0211 in the same period last year[4] - Net loss attributable to the parent company was CNY -10,040,496.02, compared to CNY -8,742,676.77 in the previous period, indicating a worsening of approximately 14.8%[20] Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of ¥4,836,758.99, a 79.54% increase compared to a net outflow of ¥23,640,127.59 last year[4] - The net cash flow from operating activities was -$4,836,758.99, an improvement from -$23,640,127.59 in the previous period[22] - Cash inflow from operating activities was CNY 41,202,488.27, down from CNY 46,288,023.21, a decrease of about 10.4% year-over-year[21] - Total cash outflow from operating activities decreased to $46,039,247.26 from $69,928,150.80[22] - Cash inflow from investment activities increased significantly to $86,578,478.38 compared to $46,581,555.73 in the prior period[22] - The net cash flow from investment activities was -$36,775,305.73, a decline from $13,456,988.93 previously[22] - Cash inflow from financing activities totaled $3,709,560.00, down from $25,931,612.24 in the last period[22] - The net cash flow from financing activities was -$147,635.85, a significant drop from $24,469,778.91[22] - The net increase in cash and cash equivalents decreased by 391.43% compared to the previous year, influenced by operating, investing, and financing activities[10] - The ending balance of cash and cash equivalents decreased to $3,439,716.44 from $17,684,279.51[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥762,219,967.93, down 2.76% from ¥783,866,026.52 at the end of the previous year[4] - Total current assets decreased from 155,969,514.43 RMB to 136,752,293.30 RMB, a reduction of approximately 12.3%[16] - Total liabilities decreased to CNY 364,114,607.47 from CNY 372,260,377.26, a decline of approximately 2.9%[17] - Current liabilities totaled CNY 170,971,610.83, down from CNY 176,987,637.83, reflecting a decrease of about 3.4%[17] - Non-current liabilities decreased to CNY 193,142,996.64 from CNY 195,272,739.43, a reduction of approximately 1.1%[17] - Total equity decreased to CNY 398,105,360.46 from CNY 411,605,649.26, indicating a decline of about 3.3%[17] Expenses - Sales expenses decreased by 47.94% year-on-year, primarily due to reduced product sales and lower market development investments[9] - R&D expenses fell by 50.95% compared to the previous year, reflecting a decrease in research investments[9] - Total operating costs decreased to CNY 51,367,471.72 from CNY 57,356,433.81, a reduction of about 10.4% year-over-year[19] Other Income and Transactions - Other income increased by 197.15% year-on-year, mainly due to higher government subsidy income[9] - The total amount of related party transactions with Ningbo Shuangcheng Pharmaceutical Co., Ltd. is 3,748,680.00 RMB, covering a three-year contract[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 79,029[12] - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 32.92% of shares, totaling 136,516,546 shares[12] Strategic Decisions - The company plans to terminate the acquisition of 100% equity in Ningbo Aola Semiconductor Co., Ltd. due to disagreements on transaction terms[13] - The company is actively pursuing strategic transactions and partnerships to enhance its market position[13] Accounting and Audit - The company did not undergo an audit for the first quarter report[23] - The new accounting standards will be first implemented starting in 2025[24]

Financial Performance - The company's operating revenue for 2024 was approximately ¥174.21 million, a decrease of 26.16% compared to ¥235.93 million in 2023[21]. - The net profit attributable to shareholders for 2024 was a loss of approximately ¥78.30 million, representing a 54.32% increase in losses compared to a loss of ¥50.74 million in 2023[21]. - The net cash flow from operating activities for 2024 was negative ¥40.83 million, a decline of 450.76% compared to positive cash flow of ¥11.64 million in 2023[21]. - The total assets at the end of 2024 were approximately ¥783.87 million, a decrease of 2.41% from ¥803.25 million at the end of 2023[21]. - The net assets attributable to shareholders decreased by 16.56% to approximately ¥393.41 million at the end of 2024, down from ¥471.49 million at the end of 2023[21]. - The basic and diluted earnings per share for 2024 were both negative ¥0.19, a decline of 58.33% compared to negative ¥0.12 in 2023[21]. - The weighted average return on net assets for 2024 was negative 18.10%, a decrease of 7.86% from negative 10.24% in 2023[21]. - The company reported a significant increase in losses from non-recurring gains and losses, with a net profit of negative ¥71.71 million in 2024 compared to negative ¥24.14 million in 2023, marking a 197.05% increase in losses[21]. Revenue Breakdown - The company's total revenue for the first quarter was ¥42,761,740.63, while the fourth quarter revenue was ¥47,246,306.92, indicating fluctuations throughout the year[25]. - The net profit attributable to shareholders for the fourth quarter was -¥40,467,047.98, showing a significant loss compared to the first quarter's loss of -¥8,742,676.77[25]. - The net cash flow from operating activities was negative in three out of four quarters, with the highest cash flow of ¥3,797,914.60 occurring in the third quarter[25]. - The industrial segment generated CNY 129.21 million, representing 74.17% of total revenue, but saw a 40.89% decline compared to the previous year[53]. - The service sector revenue increased by 159.49% year-on-year, reaching CNY 45.00 million[53]. - The peptide product line accounted for 47.42% of total revenue, totaling CNY 82.61 million, down 27.00% from the previous year[53]. - The company reported a significant increase in contract research revenue, which rose by 223.05% to CNY 40.29 million[53]. Research and Development - Research and development investment for 2024 was CNY 39.97 million, accounting for 22.95% of operating revenue[46]. - The company is actively engaged in expanding its product pipeline and enhancing its research capabilities in response to evolving industry regulations and market demands[30]. - The company has advanced its research and development in polypeptide products, focusing on high market potential and complex synthesis[39]. - The company is currently developing multiple new products (SC-C139, SC-C116, SC-C140, SC-C143, SCH-009) aimed at enhancing its product line and core competitiveness[64]. - The company plans to accelerate R&D efforts, particularly in peptide APIs and formulations, while enhancing the sales team to boost product sales post-consistency evaluation[88]. Market and Industry Trends - The pharmaceutical manufacturing industry in China saw a revenue of ¥2,529.85 billion in 2024, with a profit total of ¥34.207 billion, reflecting a 1.1% decline from the previous year[29]. - The domestic pharmaceutical industry is experiencing a shift towards community hospitals and pharmacies, indicating a changing market landscape[84]. - The market for synthetic peptide drugs is expected to grow due to increasing demand driven by rising income levels and health awareness among residents[85]. - The company faces challenges from intensified competition in the peptide drug sector, including price reductions from centralized procurement policies[86]. Risk Factors - The company faces various risks including industry policy changes, drug price reductions, and financial risks, which may impact future operations[5]. - The company faces talent retention risks, particularly in high-level technical roles for new drug development, and is implementing diverse incentive mechanisms to attract and retain talent[97]. - Financial risks are highlighted due to increasing export business and potential foreign exchange fluctuations, with strategies in place to mitigate these risks through enhanced product value and financial management practices[97]. - The company is concerned about international trade environment risks that could affect resource availability and customer retention, potentially impacting production and costs[99]. Governance and Compliance - The company held two shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[104]. - The board of directors convened seven times, demonstrating diligence in governance and decision-making processes[106]. - The company has established a performance evaluation system for directors and senior management, ensuring transparency and accountability[106]. - The independent directors actively participated in decision-making and provided independent opinions on major issues[106]. - The company has established a robust financial accounting system, ensuring independent financial decision-making[111]. Environmental Initiatives - Environmental protection investments totaled approximately CNY 3.23 million, with upgrades to wastewater treatment systems and online monitoring systems implemented[48]. - The company achieved a 15% reduction in natural gas consumption after low-nitrogen transformation of two boilers, with nitrogen oxide emissions below 50 mg/Nm³[161]. - The company has implemented a dual A/O process for wastewater treatment to enhance pollutant treatment efficiency in 2024[160]. - The company has established an emergency response plan for environmental incidents, revised in May 2024, and conducted emergency drills[160]. Shareholder Commitments - The company has committed to fulfilling its obligations as a controlling shareholder and to ensure that related parties do not engage in transactions that infringe on the rights of other shareholders[166]. - The commitments are intended to prevent any conflicts of interest and ensure fair treatment of all shareholders[166]. - The company will ensure that any unavoidable related party transactions will comply with national laws and regulations, as well as the company's articles of association[168]. - The company will prioritize the acquisition of assets or equity related to competing businesses under equal conditions if such competition arises[168]. Dividend Policy - The company plans to distribute dividends in cash or a combination of cash and stock, prioritizing cash dividends[170]. - The company aims to maintain a cash dividend policy with a cumulative cash distribution of no less than 30% of the average distributable profit over the past three years[170]. - Cash dividends will be distributed annually, with conditions including positive distributable profits and sufficient cash flow[170].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

抄底！中央汇金17.6亿重仓医药"双子星"，或将诞生下一个双成药业！ 注意！A股惊现"主力"百亿级抄底信号 资本市场正在见证历史性时刻！素有"金融稳定器"之称的中央汇金，继2019年精准抄底北方华创（股价 四年暴涨4800%）后，再度祭出重磅操作——斥资17.6亿元战略布局医药板块，其持仓动向或将催生年 度超级妖股！ 顶层设计定调万亿蓝图：4月2日，国家药监局发布《优化医疗器械全周期监管举措（征求意见稿）》， 剑指高端医疗器械创新生态构建，国务院办公厅此前明确规划：2029年医药产业规模突破2万亿，复合 增速超12%（远超GDP增速）。 硬核技术突破全球瞩目：海博为药业KRAS G12D抑制剂获FDA临床许可，全球首个攻克"不可成药"靶 点的中国药企，中国药企通过cGMP认证数量同比激增87%，国际化进程全面提速。 刚需市场持续扩容：联合国粮农组织最新预测：2040年全球兽用抗生素需求达12.9万吨，国内创新药市 场年均增速18.6%，慢病领域用药规模已突破6000亿。 国家队相中的"双子星"， 想知晓的朋友来 主 页 经过对十大券商研报的交叉验证，锁定两家获中央汇金重仓的医药核心标的： 信立泰，手握全球首个 ...

Core Viewpoint - The article highlights the presence of Shenzhen Stock Connect seats in 17 stocks on the weekly leaderboard, indicating significant net buying activity and overall positive market performance for these stocks [1] Group 1: Net Buying Activity - A total of 17 stocks appeared on the leaderboard, with 12 showing net buying from Shenzhen Stock Connect seats [1] - The stocks with the highest net buying amounts were Satellite Chemical (58,960.09 million), Tuo Wei Information (23,414.60 million), and Lakala (8,096.46 million) [1] - The average increase for the stocks with net buying was 14.13%, outperforming the Shanghai Composite Index, which rose by 0.56% [1] Group 2: Stock Performance - The stock with the largest increase was Hai Lian Jin Hui, which saw a cumulative rise of 46.57% over the week [1] - Other notable performers included Satellite Chemical (21.43% increase) and Lakala (23.83% increase) [1] - The stocks with the highest turnover rates included Tuo Wei Information (68.12%) and Lakala (123.35%) [1] Group 3: Net Selling Activity - Five stocks experienced net selling, with the largest net sell amounts recorded for Ying Wei Ke (12,449.79 million) and Wuhan Fan Gu (4,295.78 million) [1] - The net selling stocks included Ying Wei Ke (-8.93% change) and Wuhan Fan Gu (28.87% increase despite net selling) [1]

截至4月24日收盘，CRO概念上涨0.96%，位居概念板块涨幅第9，板块内，38股上涨，金凯生科20%涨 停，双成药业、河化股份、凯莱英等涨停，峆一药业、博腾股份、昊帆生物等涨幅居前，分别上涨 6.50%、5.35%、4.50%。跌幅居前的有星昊医药、康鹏科技、蔚蓝生物等，分别下跌8.43%、4.30%、 3.46%。 今日涨跌幅居前的概念板块 | 业 | | --- | | 603259 | 药明康 | 0.36 | 1.49 | 2800.31 | 1.32 | | --- | --- | --- | --- | --- | --- | | | 德 | | | | | | 300363 | 博腾股 | 5.35 | 5.1 1 | 2230.39 | 5.99 | | | 份 | | | | | | 300725 | 药石科 | 0.38 | 4.14 | 1420.31 | 6.43 | | | 技 | | | | | | 300347 | 泰格医 | 0.35 | 1.99 | 1315.18 | 2.54 | | | 药 | | | | | | | 圣诺生 | | | | | | 688117 | ...

双成药业（002693）盘中涨停，上演地天板，成交额9.06亿元。 ...

证券代码：002693 证券简称：双成药业 公告编号：2025-018 海南双成药业股份有限公司 股票交易异常波动及风险提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要风险提示： 1、公司于 2025 年 1 月 18 日在《中国证券报》《证券时报》和巨潮资讯网 （www.cninfo.com.cn）披露了《2024 年度业绩预告》（公告编号：2025-003）。 经公司财务部门初步测算（未经审计），预计公司 2024 年度归属于上市公司股东 的净利润为负值，且扣除后营业收入为 14,000 万元至 18,000 万元。根据《深圳 证券交易所股票上市规则》的相关规定，公司股票交易将在 2024 年年度报告披 露后可能被实施退市风险警示（股票简称前冠以"*ST"字样）。敬请广大投资者 注意投资风险。 2、股票异常波动风险 公司分别于 2025 年 4 月 15 日、2025 年 4 月 17 日披露《股票交易异常波动 及风险提示性公告》（公告编号：2025-015、2025-016）。公司股票（证券简称： 双成药业，证券代码：002693）收盘价 ...